Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;8(2):e1002381.
doi: 10.1371/journal.pcbi.1002381. Epub 2012 Feb 23.

The efficiency of the human CD8+ T cell response: how should we quantify it, what determines it, and does it matter?

Affiliations

The efficiency of the human CD8+ T cell response: how should we quantify it, what determines it, and does it matter?

Marjet Elemans et al. PLoS Comput Biol. 2012.

Abstract

Multidisciplinary techniques, in particular the combination of theoretical and experimental immunology, can address questions about human immunity that cannot be answered by other means. From the turnover of virus-infected cells in vivo, to rates of thymic production and HLA class I epitope prediction, theoretical techniques provide a unique insight to supplement experimental approaches. Here we present our opinion, with examples, of some of the ways in which mathematics has contributed in our field of interest: the efficiency of the human CD8+ T cell response to persistent viruses.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. CD8+ T cells recognise virally infected cells via their T cell receptor (TCR).
The TCR binds complexes of viral peptides and HLA class I molecules at the surface of virus-infected cells. Following CD8+ T cell recognition of the infected cell, the CD8+ T cell effector mechanisms are triggered. CD8+ effector mechanisms can be lytic (killing of the infected cell) and/or non-lytic (secretion of cytokines such as IFNg and TNFa which reduce the probability of cell infection and viral production).
Figure 2
Figure 2. Proposed mechanism to explain inhibitory KIR enhancement of HLA class I associations.
KIR-HLA associations are typically attributed to direct NK action (a). However, Seich al Basatena's observations do not appear to be compatible with direct NK killing for four reasons. Firstly, most of the HLA molecules which were enhanced do not bind KIR2DL2. Secondly, both protective and detrimental HLA associations were enhanced. Thirdly, KIR2DL2 with or without its C1 ligand (i.e., not in the context of a particular protective or detrimental HLA allele) had no effect on any outcome for HCV or HTLV-1. And finally, the protective effect of binding HBZ was enhanced, and NK cells display some peptide specificity, but such marked protein specificity is more reminiscent of T cells . Instead they hypothesise that the downstream effectors are CD8+ T cells (b). They postulate that KIR2DL2 enhances CD8+ T cell responses by increasing the survival of memory CD8+ T cells. Either because (i) inhibitory KIR on CD8+ T cells are associated with reduced activation induced cell death and protection from exhaustion – or (ii) inhibitory KIR on NK cells reduce NK-killing of activated CD8+ T cells , .
Figure 3
Figure 3. The variation in outcome that can be explained by individual HLA class I alleles in HIV-1, HTLV-1 and HCV infections.
The explained fraction (EF) was calculated following Nelson ; data for HCV and HTLV-1 were taken from , and data for HIV-1 were taken from , . 95% confidence intervals were estimated by bootstrapping the data 5,000 times, trimming the 5% extremes, and then calculating the range in which 95% of the remaining data lay. Due to linkage between the HLA alleles, the EF is not additive; so for instance, in HTLV-1 infection, the three alleles HLA-A*02, C*08, and B*54 together only explain 6.6% of the outcome. The outcomes explained are HCV: spontaneous clearance v persistence; HTLV-1: asymptomatic carriage v HAM/TSP; HIV-1: elite control v viremic control v progression.

Similar articles

Cited by

References

    1. Wick WD, Yang OO, Corey L, Self SG. How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill? J Virol. 2005;79:13579–13586. - PMC - PubMed
    1. Chun TW, Justement JS, Sanford C, Hallahan CW, Planta MA, et al. Relationship between the frequency of HIV-specific CD8+ T cells and the level of CD38+CD8+ T cells in untreated HIV-infected individuals. Proc Natl Acad Sci U S A. 2004;101:2464–2469. - PMC - PubMed
    1. Gea-Banacloche JC, Migueles SA, Martino L, Shupert WL, McNeil AC, et al. Maintenance of large numbers of virus-specific CD8+ T cells in HIV-infected progressors and long-term nonprogressors. J Immunol. 2000;165:1082–1092. - PubMed
    1. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, et al. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol. 2003;77:5037–5038. - PMC - PubMed
    1. Boyd MA, Dixit NM, Siangphoe U, Buss NE, Salgo MP, et al. Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). J Infect Dis. 2006;194:1319–1322. - PubMed

Publication types